Magnetic Vascular Embolic Agent for Enhanced Radiofrequency Ablation and Immunotherapy in Hepatocellular Carcinoma

This abstract describes the development of a magnetic vascular embolic agent (Thrombin-ZnTA-Fe3O4-PFP) for enhancing the efficacy of radiofrequency ablation (RFA) in the treatment of hepatocellular carcinoma (HCC). The agent is designed to address the limitations of conventional RFA and vascular embolization by simultaneously embolising tumor vessels, inhibiting lactic acid production, and alleviating anaerobic glycolysis-associated immunosuppression.

The study highlights the following key findings:

• Magnetic Targeting: The agent employs a magnetic targeting strategy, utilizing an external ferromagnet to enhance tumor-site accumulation and reduce the toxicity of thrombin.
• Enhanced RFA Efficacy: Thrombin-ZnTA-Fe3O4-PFP effectively embolises tumor vessels and enhances the efficacy of RFA, leading to improved tumor ablation.
• Lactic Acid Inhibition: The released Zn2+ from the agent significantly attenuates lactic acid production by interfering with NAD+ loss and inhibiting glycolysis. This reduces the immunosuppressive microenvironment associated with lactic acid accumulation.
• Enhanced Immunotherapy: The combination of Thrombin-ZnTA-Fe3O4-PFP with anti-programmed cell death protein-1 antibody (aPD-1) immune checkpoint blockade triggers a robust antitumor response, targeting both primary and distant tumors.

The study suggests that this combinational therapy offers a promising approach for combating HCC with minimal metastatic risk. However, the abstract lacks details on the sample size, methods used for efficacy assessment, potential limitations, and future research directions. Further investigation is needed to fully understand the clinical implications and long-term outcomes of this novel treatment strategy.